Voclosporin is a next generation calcineurin inhibitor that Isotechnika has licensed to Lux for ophthalmic indications.
Isotechnika Inc. announced on Thursday that their partner, Lux Biosciences, Inc., reported the results from the three Phase 3 LUMINATE trials investigating voclosporin oral capsule (LUVENIQ(TM) or LX211) for the treatment of uveitis.
The data show a positive effect on ocular inflammation and a safety profile consistent with the expected use in uveitis.
Following full analysis of the data, the results of the LUMINATE clinical trials will be submitted for publication and presented at upcoming conferences. In parallel, Lux Biosciences will be preparing submissions for approval.
LUMINATE Program enrolled 558 patients in 7 countries including United States, Canada, United Kingdom, France, Germany, Austria and India.
Voclosporin is designed for use as an oral immune-modulatory agent to treat the forms of non-infectious uveitis that require systemic treatment, including posterior, intermediate and panuveitis, allowing for tapering of systemic corticosteroids to 5 mg or less per day.